Vutiglabridin is under clinical development by Glaceum and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vutiglabridin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HSG-4112 is under development for the treatment of obesity, overweight , Type 2 Diabetes Mellitus (T2DM), age related macular degeneration, non-alcoholic steatohepatitis (NASH), Parkinson’s disease and unspecified indication. The drug candidate is a first-in class hydrophobic isoflavonoid molecule administered through oral route in form of tablet. The drug candidate is a new chemical entity.
For a complete picture of Vutiglabridin’s drug-specific PTSR and LoA scores, buy the report here.